Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Gunjan L. Shah, Karlo Perica, Katherine Nagel, Erica Payson, Kinga K. Hosszu, David J. Chung, Heather J. Landau, Michael Scordo, Malin Hultcrantz, Neha Korde, Kylee H Maclachlan, Urvi A. Shah, Carlyn Rose Tan, Hamza Hashmi, Alexander M. Lesokhin, Sridevi Rajeeve, Saad Z. Usmani, Sham Mailankody, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 4850.

https://doi.org/10.1182/blood-2024-212230

Published: 2024

Journal Articles

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2024-208094

Published: 2024

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2024-208490

Published: 2024

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Blood (2024) 144 (Supplement 1): 6944.

https://doi.org/10.1182/blood-2024-212006

Published: 2024

Journal Articles

Belantamab Mafodotin , nirogacestat and Pomalidomide for Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7077.

https://doi.org/10.1182/blood-2024-211857

Published: 2024

Journal Articles

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Charlotte FM Hughes, Andrew Lin, Maria Bromberg, Sean M. Devlin, Amethyst Saldia, Danielle E Engstler, Danielle M Hanley, Yetunde Aremu, Martin Donach, Elizabeth Hoover, Oscar B Lahoud, Arnab Ghosh, Moneeza Walji, Miguel-Angel Perales, Michael Scordo, Sergio A. Giralt, Gunjan L. Shah, Parastoo B Dahi

Blood (2024) 144 (Supplement 1): 6492.

https://doi.org/10.1182/blood-2024-208310

Published: 2024

Journal Articles

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2024-207977

Published: 2024

Journal Articles

Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

Blood (2024) 144 (Supplement 1): 6990.

https://doi.org/10.1182/blood-2024-209891

Published: 2024

Journal Articles

Treatment Patterns of Immunoglobulin Replacement Therapy Among Patients with Multiple Myeloma in the United States: A Real-World Analysis

Fidelia Ida, Bharat Ramakrishna, Kaz Nasserinejad, Adriana Radu, John-Philip Lawo, Xiang Zhang, David Gardiner, Lara Yoon, John Shen, Elizabeth C. Dabrowski, Saarah Khan, Gabriela Espinoza, Zainab Shahid, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2024-206999

Published: 2024

Journal Articles

Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis

Fidelia Ida, Bharat Ramakrishna, Kaz Nasserinejad, Adriana Radu, John-Philip Lawo, Xiang Zhang, David Gardiner, Lara Yoon, Elizabeth C. Dabrowski, John Shen, Monica Iyer, Hannah Kreisberg, Gabriela Espinoza, Zainab Shahid, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 3346.

https://doi.org/10.1182/blood-2024-205221

Published: 2024

Journal Articles

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy As an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Chanel Davidoff, Katarzyna Ibanez, Sinchun Hwang, Ilan Goldstein, Darren R. Feldman, Boglarka Gyurkocza, Sergio A. Giralt, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Grigory Syrin, Gunjan L. Shah, Christian M. Custodio, Franchesca Konig

Blood (2023) 142 (Supplement 1): 6978.

https://doi.org/10.1182/blood-2023-189328

Published: 2023

Journal Articles

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Toshihisa Satta, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Pamela Susman, Amandeep Singh, Marco Calafiore, Sergio A. Giralt, Miguel-Angel Perales, Jianmin Chen, Simon Li, Jonathan U. Peled, Marcel R.M. van den Brink, Alan M. Hanash, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2023-181269

Published: 2023

Journal Articles

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2023-179413

Published: 2023

Journal Articles

Dynamics of Radiomic Features Following Bridging Therapy Determine CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome

Blood (2023) 142 (Supplement 1): 2123.

https://doi.org/10.1182/blood-2023-187763

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2023-181868

Published: 2023

Journal Articles

A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial

Blood (2023) 142 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2023-182878

Published: 2023

Journal Articles

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2023-189349

Published: 2023

NARROW

Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Belantamab Mafodotin , nirogacestat and Pomalidomide for Patients with Relapsed/Refractory Multiple Myeloma

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

Treatment Patterns of Immunoglobulin Replacement Therapy Among Patients with Multiple Myeloma in the United States: A Real-World Analysis

Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy As an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

A Comparative Analysis of Infectious Complications in Patients with Multiple Myeloma Treated with BCMA-Targeted Bispecific Antibodies and CAR T-Cell Therapy

Dynamics of Radiomic Features Following Bridging Therapy Determine CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) and Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd) As Induction Therapy in Newly Diagnosed Multiple Myeloma

A Whole Foods Plant-Based Weight Loss Intervention Improves Quality of Life, Metabolic, Microbiome and Immune Profile in MGUS/SMM As Well As Progression Trajectory in a Subset - the Nutrivention Trial

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only